These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27765925)

  • 21. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
    Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
    Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
    Zhang J; Guo L; Liu X; Li W; Ying J
    Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential clinicopathologic features in microsatellite-unstable gastric cancers with and without MLH1 methylation.
    Kim KJ; Lee TH; Cho NY; Yang HK; Kim WH; Kang GH
    Hum Pathol; 2013 Jun; 44(6):1055-64. PubMed ID: 23266441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis.
    Kang HJ; Lee IS; Park YS; Ho WJ; Sohn D; Ahn JY; Yook JH; Kim BS
    Ann Surg Oncol; 2016 Oct; 23(11):3684-3692. PubMed ID: 27221363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features.
    Tsugawa K; Yonemura Y; Hirono Y; Fushida S; Kaji M; Miwa K; Miyazaki I; Yamamoto H
    Oncology; 1998; 55(5):475-81. PubMed ID: 9732228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization.
    Choi J; Lee HE; Kim MA; Jang BG; Lee HS; Kim WH
    PLoS One; 2014; 9(11):e111658. PubMed ID: 25364819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.
    Tsapralis D; Panayiotides I; Peros G; Liakakos T; Karamitopoulou E
    World J Gastroenterol; 2012 Jan; 18(2):150-5. PubMed ID: 22253521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer.
    Jin EH; Lee DH; Jung SA; Shim KN; Seo JY; Kim N; Shin CM; Yoon H; Jung HC
    World J Gastroenterol; 2015 Jan; 21(2):571-7. PubMed ID: 25593477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
    Pala EE; Bayol U; Ozguzer A; Akman O
    Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of HER2 and p53 Mutations by Sequence Analysis Method and EGFR/Chromosome 7 Gene Status by Fluorescence in Situ Hybridization for the Predilection of Targeted Therapy Modalities in Immunohistochemically Triple Negative Breast Carcinomas in Turkish Population.
    Pala EE; Bayol U; Keskin EU; Ozguzer A; Kucuk U; Ozer O; Koc A
    Pathol Oncol Res; 2015 Sep; 21(4):1223-7. PubMed ID: 26060045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
    Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.
    Janbabai G; Oladi Z; Farazmandfar T; Taghvaei T; Naghshvar F
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1945-52. PubMed ID: 25820598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 expression and its clinicopathological features in resectable gastric cancer.
    Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
    Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
    Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
    Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.